- Home
- TSBX
TSBX
Turnstone Biologics Corp.
as 11-14-2024 10:36am EST
Stocks
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | LA JOLLA |
| Market Cap: | N/A | IPO Year: | 2023 |
| Target Price: | $4.75 | AVG Volume (30 days): | 600.5K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.44 - $5.75 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | -73.66% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Turnstone Biologics Corp. News
TSBX Breaking Stock News: Dive into TSBX Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Turnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
GlobeNewswire
9 days ago
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
TipRanks
a month ago
Turnstone Biologics Streamlines Operations and Leadership
MT Newswires
a month ago
Turnstone Biologics Cuts Workforce by 60% to Focus on Phase 1 Cancer Program
BioPharma Dive
a month ago
FDA clears Roche breast cancer drug; Turnstone lays off 60% of staff
GlobeNewswire
a month ago
Turnstone Biologics Announces Strategic Restructuring to Prioritize Portfolio and Extend Financial Runway
GlobeNewswire
3 months ago
Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
GlobeNewswire
3 months ago
Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer
Compare TSBX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TSBX Turnstone Biologics Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.